AIMS: To evaluate the relationship between asymmetric dimethylarginine (ADMA) and nocturia.
METHODS: A total of 862 community-based elderly individuals were examined in this cross-sectional study (mean age, 72.1 years). We measured nocturnal void frequency and serum ADMA levels. Nocturia was ascertained for a frequency of two or more nocturnal voids.
RESULTS: Nocturia was observed in 262 (30.4%) participants. Univariate logistic regression models revealed a significant association between prevalent nocturia and ADMA levels (crude odds ratio [OR], 1.556 (2nd vs. 1st tertile); 95% confidence interval [CI], 1.066-2.270; P = 0.022; crude OR, 2.114 (3rd vs. 1st tertile); 95% CI, 1.453-3.072; P < 0.001). Univariate logistic regression models also revealed marginal to significant associations between prevalent nocturia and age, gender, calcium channel blocker use, nitric oxide-related drug use, diabetes, estimated glomerular filtration rate, insomnia, benign prostatic hyperplasia, overnight urine volume, and endogenous melatonin levels. In the multivariate model simultaneously adjusted for the former variables, higher ADMA levels were significantly associated with higher OR for nocturia (adjusted OR, 1.556 (3rd vs. 1st tertiles); 95% CI, 1.010-2.397; P = 0.045).
CONCLUSION: Serum ADMA levels, an endogenous inhibitor of nitric oxide synthase, are significantly associated with prevalent nocturia in the general elderly population.
Written by:
Obayashi K, Saeki K, Kurumatani N. Are you the author?
Department of Community Health and Epidemiology, Nara Medical University School of Medicine, Nara, Japan.
Reference: Neurourol Urodyn. 2014 Jul 25. Epub ahead of print.
doi: 10.1002/nau.22647
PubMed Abstract
PMID: 25066965
